Niiki Pharma Inc.
Records under this name other than patents Niiki Pharma Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,362,266 | Method of manufacturing a ruthenium complex Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,089,578 | Method of treating neuroendocrine tumors Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,283,208 | Medicaments and methods for treating cancer Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,135,212 | Method for treating osteoporosis, osteopenia or low bone mineral density Formerly held Lapsed on the fee record Ended Oct 5, 2025 · USPTO record | Lapsed on the fee record | Ended Oct 5, 2025 | USPTO record |
| US 9,725,471 | Method to prevent cancer metastasis to bone Formerly held Lapsed on the fee record Ended Aug 8, 2025 · USPTO record | Lapsed on the fee record | Ended Aug 8, 2025 | USPTO record |
| US 10,463,657 | Method for treating osteoporosis, osteopenia or low bone mineral density Formerly held Lapsed on the fee record Ended Nov 5, 2023 · USPTO record | Lapsed on the fee record | Ended Nov 5, 2023 | USPTO record |
| US 7,919,486 | Use of gallium(III) complexes for the treatment of melanomas Formerly held Lapsed on the fee record Ended Apr 5, 2023 · USPTO record | Lapsed on the fee record | Ended Apr 5, 2023 | USPTO record |
| US 7,338,946 | Compositions containing a ruthenium(III) complex and a heterocycle Formerly held Term ended Term ended Dec 16, 2022 · USPTO record | Term ended | Term ended Dec 16, 2022 | USPTO record |
| US 7,485,659 | Anticancer compositions, and methods of making and using the same Formerly held Term ended Term ended Jan 28, 2022 · USPTO record | Term ended | Term ended Jan 28, 2022 | USPTO record |
| US 7,589,084 | Anticancer compositions, and methods of making and using the same Formerly held Term ended Term ended Jan 28, 2022 · USPTO record | Term ended | Term ended Jan 28, 2022 | USPTO record |